Mucosal melanoma cancer cells capable of mediating the compensatory switch from cyclin D1 to cyclin D2, important molecules that cells employ to replicate, exhibited greater resistance to trametinib’s downstream suppressive effects on cyclin D1. This evidence concerns the gene CCND2 and cancer.